US OptionsDetailed Quotes
IVVD241220C5000
- 0.05
- 0.000.00%
15min DelayClose Dec 20 16:00 ET
0.00High0.00Low
0.05Open0.05Pre Close0 Volume63 Open Interest5.00Strike Price0.00Turnover0.00%IV1039.95%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier-2DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma8.88Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Invivyd Stock Discussion
Sign in to post a comment
$ABVC BioPharma (ABVC.US)$ - Progress continues in our ADHD program with Phase IIb trials at multiple prominent sites. We aim to have an interim report by Q4 2024. ABV-1601 for MDD in cancer patients has completed Phase I study preparation, including the Site Initiation Visit (SIV). The study is set to initiate by the end of 2024.
$Ascent Solar Technologies (ASTI.US)$- Following delivery and the successful completion of the on-orbi...
$Ascent Solar Technologies (ASTI.US)$- Following delivery and the successful completion of the on-orbi...
26
7
7
$Invivyd (IVVD.US)$
Invivyd Announces New England Journal of Medicine Publishes Letter to the Editor Highlighting Immunobridging Pathway Leading to PEMGARDA™ (pemivibart) Emergency Use Authorization; Comments on Adjacent Third-Party Letter to the Editor
The New England Journal of Medicine (NEJM) published a Letter to the Editor describing PEMGARDA™ (pemivibart)'s immunobridging emergency use authorization pathway and an updated correlate of protection curve for COVID-19 prevention. The letter...
Invivyd Announces New England Journal of Medicine Publishes Letter to the Editor Highlighting Immunobridging Pathway Leading to PEMGARDA™ (pemivibart) Emergency Use Authorization; Comments on Adjacent Third-Party Letter to the Editor
The New England Journal of Medicine (NEJM) published a Letter to the Editor describing PEMGARDA™ (pemivibart)'s immunobridging emergency use authorization pathway and an updated correlate of protection curve for COVID-19 prevention. The letter...
1
$Invivyd (IVVD.US)$ Benzinga· 3 mins ago
Invivyd Publishes CANOPY Phase 3 Trial Data Preprints Showing Long-Term COVID-19 Protection By Pemivibart Against JN.1 Sublineages; Novel Method For Predicting Monoclonal Antibody Activity Against Emerging Variants Detailed In BioRxiv
Invivyd Publishes CANOPY Phase 3 Trial Data Preprints Showing Long-Term COVID-19 Protection By Pemivibart Against JN.1 Sublineages; Novel Method For Predicting Monoclonal Antibody Activity Against Emerging Variants Detailed In BioRxiv
$Invivyd (IVVD.US)$ Invivyd Phase 3 Long-Term Exploratory Clinical Efficacy Data Shows PEMGARDA (Pemivibart) Provided Substantial Protection From Symptomatic COVID-19 Versus Placebo Over Six Months of Follow-Up, With No Additional Doses, In Immunocompetent Participants
GlobeNewswire· 12 mins ago
Following strong protection (84% relative risk reduction versus placebo) demonstrated through month 6 with pemivibart, CANOPY clinical trial participants were followed for an additional six-month pe...
GlobeNewswire· 12 mins ago
Following strong protection (84% relative risk reduction versus placebo) demonstrated through month 6 with pemivibart, CANOPY clinical trial participants were followed for an additional six-month pe...
2
$Invivyd (IVVD.US)$
Invivyd to Present PEMGARDA™ (pemivibart) Data at Infectious Disease Week (IDWeek) 2024
Invivyd (Nasdaq: IVVD) announced upcoming presentations of pemivibart data from its Phase 1 and Phase 3 clinical trials at IDWeek 2024 in Los Angeles, October 16-19, 2024. The presentations include:
An oral presentation on clinical efficacy endpoints from the Phase 3 CANOPY Study
A poster on results from a Phase 1 first-in-human study
A poster on pharmacokinetics and serum virus neutral...
Invivyd to Present PEMGARDA™ (pemivibart) Data at Infectious Disease Week (IDWeek) 2024
Invivyd (Nasdaq: IVVD) announced upcoming presentations of pemivibart data from its Phase 1 and Phase 3 clinical trials at IDWeek 2024 in Los Angeles, October 16-19, 2024. The presentations include:
An oral presentation on clinical efficacy endpoints from the Phase 3 CANOPY Study
A poster on results from a Phase 1 first-in-human study
A poster on pharmacokinetics and serum virus neutral...
1
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
$Invivyd (IVVD.US)$ i support this stock
New targets for next week:
$Invivyd (IVVD.US)$ - makes COVID antibodies, w/ a phase 3 trial completing soon.
$ReNew Energy Global (RNW.US)$ - unconventional and renewable energy company in India.
$Vivid Seats (SEAT.US)$ - Online marketplace for event tickets. Good competition vs. $Live Nation Entertainment (LYV.US)$
$Array Technologies (ARRY.US)$ Tracking equipment and software for solar panels, allowing them to increase efficiency following the sun through the day.
$Invivyd (IVVD.US)$ - makes COVID antibodies, w/ a phase 3 trial completing soon.
$ReNew Energy Global (RNW.US)$ - unconventional and renewable energy company in India.
$Vivid Seats (SEAT.US)$ - Online marketplace for event tickets. Good competition vs. $Live Nation Entertainment (LYV.US)$
$Array Technologies (ARRY.US)$ Tracking equipment and software for solar panels, allowing them to increase efficiency following the sun through the day.
3
1
$Invivyd (IVVD.US)$
Invivyd Announces U.S. FDA Has Updated the PEMGARDA™ EUA Fact Sheet with Accurate SARS-CoV-2 Variant Susceptibility and PEMGARDA Activity Data
Invivyd (Nasdaq: IVVD) announced that the FDA has updated the Emergency Use Authorization (EUA) Fact Sheet for PEMGARDA™ (pemivibart) with accurate SARS-CoV-2 variant susceptibility data. The updated Fact Sheet, dated September 26, 2024, includes in vitro neutralization activity against dominant circulating variants, including KP.3....
Invivyd Announces U.S. FDA Has Updated the PEMGARDA™ EUA Fact Sheet with Accurate SARS-CoV-2 Variant Susceptibility and PEMGARDA Activity Data
Invivyd (Nasdaq: IVVD) announced that the FDA has updated the Emergency Use Authorization (EUA) Fact Sheet for PEMGARDA™ (pemivibart) with accurate SARS-CoV-2 variant susceptibility data. The updated Fact Sheet, dated September 26, 2024, includes in vitro neutralization activity against dominant circulating variants, including KP.3....
$Invivyd (IVVD.US)$ Reuters
Just
Invivyd Announces U.S. FDA Has Updated the Pemgarda™ Eua Fact Sheet With Accurate Sars-Cov-2 Variant Susceptibility and Pemgarda Activity Data
Just
Invivyd Announces U.S. FDA Has Updated the Pemgarda™ Eua Fact Sheet With Accurate Sars-Cov-2 Variant Susceptibility and Pemgarda Activity Data
No comment yet
AddiBee0925 : Hey Jag. Just a heads up. If all goes as planned, the launch for SIDU and SpaceX is on the schedule for this Friday on the 20th. I wouldn't think that it would be rescheduled so soon to the launch, at least no report has said otherwise.
Jaguar8 OP AddiBee0925 : Yes. But there might be a build up of the price before the launch just like LUNR. Hopefully it goes well.
AddiBee0925 Jaguar8 OP : yeah I'm thinking the same
Jaguar8 OP browny_440 : TNXP will be good if FDA releases decision soon
72306783 : I would like to ask, what signals or standards do you use to start building positions? I am still learning... Thank you very much for your Share
View more comments...